MDWD
MediWound Ltd.
$16.97
$0.00(0.00%)
30
Overall
--
Value
30
Tech
--
Quality
Market Cap
$206.94M
Volume
176.07K
52W Range
$14.14 - $22.51
Target Price
$31.33
Company Overview
| Mkt Cap | $206.94M | Price | $16.97 |
| Volume | 176.07K | Change | +0.00% |
| P/E Ratio | -6.8 | Open | $16.56 |
| Revenue | $20.0M | Prev Close | $16.97 |
| Net Income | $-30.2M | 52W Range | $14.14 - $22.51 |
| Div Yield | N/A | Target | $31.33 |
| Overall | 30 | Value | -- |
| Quality | -- | Technical | 30 |
No chart data available
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest News
Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP) and Mediwound (MDWD)
Howard Kim•2 days ago
MediWound Highlights Vericel’s $197 Million BARDA Contract for NexoBrid
TipRanks Auto-Generated Newsdesk•6 days ago
MediWound Sets May 6, 2026 Shareholder Meeting to Vote on Board, Auditor and CEO Bonus
TipRanks Auto-Generated Newsdesk•9 days ago
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and Mediwound (MDWD)
Catie Powers•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MDWD | $16.97 | 0% | 176.07K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |